Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 8.1% in December

Posted by Matthew Steigler on Jan 2nd, 2025

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 530,200 shares, an increase of 8.1% from the November 30th total of 490,400 shares. Based on an average trading volume of 28,200 shares, the short-interest ratio is currently 18.8 days. Currently, 9.0% of the shares of the stock are sold short.

Greenwich LifeSciences Trading Up 2.9 %

Shares of GLSI traded up $0.32 during mid-day trading on Wednesday, hitting $11.23. 42,190 shares of the company traded hands, compared to its average volume of 39,041. The stock has a market capitalization of $147.62 million, a price-to-earnings ratio of -14.04 and a beta of 1.61. The business has a 50-day moving average of $13.29 and a 200 day moving average of $14.27. Greenwich LifeSciences has a one year low of $8.00 and a one year high of $21.44.

Institutional Investors Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences in the second quarter worth about $117,000. Barclays PLC raised its stake in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares during the last quarter. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences during the third quarter worth approximately $253,000. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the second quarter valued at approximately $264,000. Finally, State Street Corp boosted its stake in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the last quarter. 4.16% of the stock is owned by institutional investors and hedge funds.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.